Back

Variant Bio expands Boehringer collaboration for cardiovascular targets, potentially exceeding $250 million

Verifying
  • Variant Bio expanded its research and license agreement with Boehringer Ingelheim into cardiovascular disease.
  • Variant Bio will receive an additional upfront payment and potential payments totaling over $250 million.
  • The collaboration builds on existing kidney-disease research and uses Variant Bio’s Inference platform.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Variant Bio expands Boehringer collaboration for cardiovascular targets, potentially exceeding $250 million - CoinPost Terminal